van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, et al. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol 2023 Jan 31:S2468-1253(22)00434.
PMID: 36736339